Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Notice of General Meeting 2019

March 13, 2019August 16, 2022 Alterity Therapeutics

Notice of General Meeting 2019

2019

Post navigation

Prana receives Orphan Designation for PBT434 for treatment of MSA

Prana receives A$3.3 million R&D Tax Incentive

Related Posts

Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program

October 19, 2021August 16, 2022

Prana’s PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration

July 3, 2017August 16, 2022

Pre-clinical evidence demonstrates PBT434 as a potential treatment for MSA

October 5, 2018August 16, 2022

Recent Posts

Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder
Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023
Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy
Appendix 4C – Q3 FY23 Quarterly Cash Flow Report
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065